biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics
Inhibikase Therapeutics is a biotech organization headquartered in Wilmington, USA. It trades on NYSE under ticker IKT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Pulmonary Arterial Hyperten
Wilmington, USA HQ
29 Employees
Public company Type
IKT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmington, USA
- Employees
- 29
- Programs
- 4
- Drugs
- 5
- Patents
- 9
IKT-001
Phase 3 · small molecule · Pulmonary Arterial Hypertension
IKT-001 for Pulmonary Arterial Hypertension is a Phase 3 program (small_molecule) at Inhibikase Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code IKT-001-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Inhibikase Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pulmonary Arterial Hypertension
- Status
- active
- Trials
- 1